|
WO2020235936A1
|
|
Asymmetric sirna inhibiting expression of pd-1
|
|
KR20200090132A
|
|
Asymmetric siRNA Inhibiting Expression of NRL
|
|
WO2020144583A1
|
|
Cell-penetrating tripodal interfering rna
|
|
WO2020122534A1
|
|
Asymmetric sirna for inhibiting expression of snai1
|
|
WO2019066519A1
|
|
Pharmaceutical composition for prevention or treatment of age-related macular degeneration containing rna complex targeting connective tissue growth factor
|
|
KR20180002528A
|
|
Compounds improving RNA interference of small interfering RNA and use thereof
|
|
EP3443093A2
|
|
Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
|
|
KR20180096330A
|
|
Asymmetric siRNA Inhibiting Expression of Genes Directed to Male Type Depilation
|
|
KR20180104075A
|
|
Treatment of atopic dermatitis and asthma using RNA complexes targeting IL4Ra, TRPA1, or F2RL1
|
|
KR20180104692A
|
|
Treatment of angiogenesis related diseases using RNA complexes targeting ANGPT2 and PDGFB
|
|
CA3005411A1
|
|
Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
|
|
CA3022872A1
|
|
Rna complexes that inhibit melanin production
|
|
US2015111948A1
|
|
RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
|
